Schubert & Co’s Sarepta Therapeutics SRPT Stock Holding History

Schubert & Co’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3	Closed	-$414	–	1309
2023 Q1	$414	Buy	+3	New	+$389	﹤0.01%	1457

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Schubert & Co's SRPT Position: Q2 2023 in Review

Schubert & Co sold out of Sarepta Therapeutics (SRPT) in Q2 2023, closing a stake of 3 shares — an estimated $414 sold.

Schubert & Co first reported a position in SRPT in Q1 2023 and held it in 1 quarter. The position peaked at $414 in Q1 2023. 404 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

Schubert & Co reported no remaining Sarepta Therapeutics position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 3 Sarepta Therapeutics shares in Q2 2023, an estimated $414.
Schubert & Co first reported a position in Sarepta Therapeutics in Q1 2023 and held it in 1 quarter.
Schubert & Co's Sarepta Therapeutics position peaked at $414 in Q1 2023.
404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.